PRIME BIO RESEARCH plc

Offer For Sale of Shares in Prime BioResearch plc, a UK based targeted-drug acquisition and development company, with a proprietary patent portfolio, specialising in personalised medicines for illness with large and growing markets, such as Obesity, Type 2 Diabetes and Cardiovascular Disorders. More can be read about this company on its website, www.primebioresearch.com.

Prime BioResearch plc
An opportunity for private investors to participate in the biotechnology revolution

St. Paul’s Equities Limited (St. Paul’s Equities) is pleased to announce the launch of an Offer for Sale of Shares in Prime BioResearch plc ("Prime BioResearch" or the "Company"), the latest in a series of pre-Initial Public Offerings (“pre-IPOs”) providing you with the opportunity to invest prior to the Company’s proposed admission to PLUS or AIM.  St. Paul’s Equities is a stockbroker authorised and regulated by the Financial Services Authority (FSA).

Prime BioResearch Offer Doc

Prime BioResearch Application

Prime BioResearch Info Sheet

Prime BioResearch is a highly targeted biotech company with the sole focus on identifying, evaluating, acquiring, developing and partnering to achieve the commercialisation of Intellectual Property (“IP”) in the area of drug candidates for personalised medicines.

Key Points

• Target indication areas of metabolic disorders, inflammatory diseases, and cardiovascular disorders
• Blockbuster potential underpinned by the acquisition of proprietary provisional patent applications and issued patents
• Through an established network of experts, achieving the filing of cost-efficient patent applications for areas not covered by existing patents.
• A world-class management team of experts with combined experience in patent law and medical research, complemented by an advisory board recognised as outstanding international scientists
• Rapid partnership capabilities for co-operation research agreements with
  leading R&D Service Providers, research institutions and universities in India, Europe and North America
• Cost-efficient search strategy for proprietary IP benefiting from cost-efficiency in the sector, with limited fixed overhead with variable expenses and scalable organisation (both up and down)
• IP acquisitions pending with leading universities and institutions in Europe and India, including two already identified cost-efficient target drugs
• Expected revenues from licensing fees, as well as upfront and milestone
  payments from follow-on and new targets made available to Big Pharma and/or Biotech Companies should enable Prime BioResearch to fully self finance from next year and onwards
• Has an independent expert valuation estimating a current market valuation of
  up to £12 million
• Has an independent valuation from a biotechnology expert to the effect that
  the pre-tax net present value to the Company of a successful drug for Type 2 Diabetes would be US$1.14 billion, and for anti-obesity would be US$1.807 billion

Business

Prime BioResearch is a targeted drug acquisition and development company. PBR
specialises in personalised medicines for illnesses with large markets. PBR initially
identifies, evaluates and acquires the most innovative patented lifescience research. PBR then develops each technology in its relevant potential applications through outsourcing and early strategic alliances. The successful projects are then sold on to healthcare marketing companies. Drug Indication Areas Metabolic disorders (Obesity and Diabetes-II) Inflammatory diseases and cardiovascular. See the company website here.

Current Drug Patents

• PBR has already acquired six promising patent applications, filed at the European Patent Office.
• Further projects have been identified and are being evaluated for acquisition.
  Expert Management
• CEO with many years relevant experience in varying capacities, i.e. surgeon,
  healthcare analyst and corporate financier, including as life science analyst
  for investment banking at Nomura and Yamaichi.
• CFO with 15 years in corporate accounting, including biotech companies.
• Scientific Advisory Board with variety of backgrounds and experience, including healthcare physician, analyst, corporate finance and biotech investment management.

Risk Warning

Shares in Prime BioResearch plc are unquoted securities and may be considered to have more risk than quoted securities and shares. The value of investments can go down as well as up. You may have difficulty selling this investment at a reasonable price and, in some circumstances; it may be difficult to sell it at any price. Do not invest in this unless you have carefully thought about whether you can afford it and whether it is right for you and should you have any doubts about the suitability of this investment please consult with a professional adviser in accordance with the Financial Services and Markets Act 2000. The share capital of the Company is not presently listed on any exchange and, whilst it is the belief of the directors of St. Paul’s Equities’ that this is the intention, this cannot be guaranteed. The information contained in this letter does not form part of any offer for sale or subscription to or solicitation to buy or subscribe for any securities or investment product(s). You should be a suitable investor on the basis that you are an existing shareholder in such similar stock(s) and/or you have previous experience in medium higher risk, unquoted and private companies and are suitably knowledgeable of the risks associated with such non-readily realisable investments in small cap unquoted or quoted companies. The Offer for Sale Document is not a prospectus and contains no offer to the public for purposes of the Prospectus Regulations 2005. St. Paul’s Equities Limited (“St. Paul’s Equities”) is authorised and regulated by the Financial Services Authority (“FSA”).

Conclusion

An opportunity for private investors to participate in the biotechnology revolution and gain from demographic shifts such as the ageing of the population. This offer may be withdrawn early if the issue becomes oversubscribed. We suggest prospective investors apply as early as possible.

Terms of the offer and applying for shares

The formal terms of the Offer are contained in the Offer for Sale of Shares Document and applications for shares are made solely on that basis. If you wish to hear and/or see more about this Offer please contact us by telephone on 020 7329 3888, or via email at info@stpaulsequities.com.

This Offer is open for a limited time only on a first come, first served basis we therefore recommend prospective investors apply as early as possible after satisfying themselves of the suitability of the investment for their circumstances and attitude to risk. Before investing in any unquoted stocks one should note the risks involved. Whilst there is often excellent opportunity to benefit by investing in companies at an early stage of their development and/or prior to a listing, there can be risks involved. Read more here.

To request further information on any St. Paul's Equities Offer contact us via e-mail here. If you wish to become a client then you will be required to read and sign the Terms & Conditions.

Call 020 7329 3888 for more info